You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Type 2 Issues Articles
Popular Type 2 Issues Articles
Highly Recommended Type 2 Issues Articles
Send a link to this page to your friends and colleagues.
This press release is an announcement submitted by Upjohn Company, and was not written by Diabetes Health.
The Glynase PresTab tablet is a patented 3 mg glyburide tablet that divides easily in two with the press of a finger. This new design allows diabetes patients to measure their prescribed daily dosage easily and accurately, with a consistent available potency between 90% and 100%.
According to the Upjohn Company, Glynase PresTab's improved potency allows patients to take a dosage lower than the already available Micronase glyburide tablet and still expect the same results. The Upjohn Company recommends that patients have their dosage readjusted by a doctor before switching from Micronase or other hypoglycemic agents to Glynase PresTab.
0 comments - Nov 1, 1992
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.